Trastuzumab Pamirtecan Shows Modest Efficacy in Breast Cancer Trial with Noted Side Effects

BioNTech and DualityBio's Phase 3 trial for trastuzumab pamirtecan in HR+/HER2-low metastatic breast cancer met its primary endpoint, showing a modest improvement in progression-free survival. However, the trial also reported a higher incidence of interstitial lung disease, including severe and fatal cases. The companies plan to discuss these results to determine the drug's future development.